| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) VA Boston Healthcare System |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000310 |
Purpose
The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.
| Condition | Intervention | Phase |
|
Cocaine-Related Disorders |
Drug: Risperidone |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control |
| Official Title: | Serotonin/Dopamine Antagonism of Cocaine Effect |
| Estimated Enrollment: | 0 |
| Study Start Date: | January 1996 |
Risperidone in low doses is compared with placebo in a 6-week randomized trial. Subjects also receive supportive counseling. Outcome measure include rating of behavior, mood, drug abuse, global function, and urine toxicology.
Eligibility
| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Cocaine abuse or dependence
Exclusion Criteria:
Dependence on other drugs. Major psychiatric illness
Contacts and Locations| United States, Rhode Island | |||||
| Brown University School of Medicine | |||||
| Providence, Rhode Island, United States, 2906 | |||||
| National Institute on Drug Abuse (NIDA) |
| VA Boston Healthcare System |
| Principal Investigator: | Lawrence Price, M.D. | Brown University |
More Information
| Study ID Numbers: | NIDA-09330-2, R01-09330-2 |
| First Received: | September 20, 1999 |
| Last Updated: | August 16, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000310 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|
